HONG KONG – Japanese biopharma Carna Biosciences Inc. and Gilead Sciences Inc., of Foster City, Calif., have signed a $470 million R&D collaboration to develop and commercialize small-molecule compounds in immuno-oncology. Under the agreement, Gilead will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Kobe, Japan-based Carna. Read More
HONG KONG – Supported by the municipal government of Chongqing in China, a joint venture between South Korean drugmaker Binex Co. Ltd. and Chinese pharmaceutical company Chongqing Zein Pharmaceutical Co. Ltd. will be set up in the third quarter of this year. Read More
HONG KONG – Shanghai-based biopharma firm Harbour Biomed Therapeutics Ltd. has inked a 10-year pact with Erasmus MC from the University Medical Center Rotterdam to grow its footprint in Europe. Both sides will develop biotherapeutics to treat cancer and immunological diseases. Read More
HONG KONG – Two Korean biotech companies, Genexine Inc. and Toolgen Inc., have agreed to merge into a single entity named Toolgenexine Inc., in order to develop novel immunotherapy drugs with gene editing technology. Read More
HONG KONG – In an era when data are more valuable than gold, China has rolled out new regulations to strengthen control of its human genetics data. Any foreign biotech companies or institutes intending to use Chinese data must engage a Chinese partner in the research project, among other new requirements. Read More
Peptidream Inc., of Kanagawa, Japan, disclosed a new peptide-drug conjugate (PDC) collaboration agreement with Novartis AG, of Basel, Switzerland. Peptidream will use its Peptide Discovery Platform System technology for the identification of macrocyclic/constrained peptides for use as PDCs against multiple targets of interest selected by Novartis. Read More
Terns Pharmaceuticals Inc., of Foster City, Calif., and Shanghai, appointed Ankang Li chief financial officer. Li will be responsible for corporate financing, financial reporting, accounting, risk management, business development and investor relations. Read More
